The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-13), Traws Pharma's share price is $0.66. Traws Pharma's Book Value per Share for the quarter that ended in Dec. 2023 was $0.51. Hence, Traws Pharma's PB Ratio of today is 1.30.
The historical rank and industry rank for Traws Pharma's PB Ratio or its related term are showing as below:
TRAW'
s PB Ratio Range Over the Past 10 Years
Min: 0.4 Med: 2.37 Max: 49.25
Current: 1.29
During the past 13 years, Traws Pharma's highest PB Ratio was 49.25. The lowest was 0.40. And the median was 2.37.
TRAW's PB Ratio is ranked better than 73.95% of 1313
companies
in the Biotechnology industry
Industry Median: 2.48
vs TRAW: 1.29
During the past 12 months, Traws Pharma's average Book Value Per Share Growth Rate was -62.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 0.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -36.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Traws Pharma was 0.70% per year. The lowest was -77.80% per year. And the median was -60.30% per year.
Back to Basics: PB Ratio
Traws Pharma PB Ratio Historical Data
The historical data trend for Traws Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Traws Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Traws Pharma's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Traws Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Traws Pharma's PB Ratio falls into.
Traws Pharma PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Traws Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Traws Pharma PB Ratio Related Terms
Thank you for viewing the detailed overview of Traws Pharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TRAW has been successfully added to your 